We’re learning more and more about type 2 inflammation every day. Read more about the latest findings and the role it plays in a number of diseases.
We’re learning more and more about type 2 inflammation every day. Read more about the latest findings and the role it plays in a number of diseases.
¹Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016; 15(1): 35-50
²Gandhi NA, Pirozzi G, Graham NM. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert review of clinical immunology. 2017 May 4;13(5):425-37.
³Cherwinski, H. M., Schumacher, J. H., Brown, K. D., & Mosmann, T. R. (1987). Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. The Journal of experimental medicine, 166(5), 1229-1244
⁴Snapper CM, Finkelman FD, Paul WE. Regulatiopn of IgG1 and IgE production by interleukin 4. Immunological reviews. 1988 Apr 1;102(1):51-75.
⁵Mosmann, T. R. & Coffman, R. L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7, 145-173 (1989).
⁶Ray, Anuradha, Timothy B. Oriss, and Sally E. Wenzel. “Emerging molecular phenotypes of asthma.” American Journal of Physiology-Lung Cellular and Molecular Physiology 308.2 (2015): L130-L140.
⁷Muraro, Antonella, et al. “Precision medicine in patients with allergic diseases: airway diseas and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology.” Journal of allergy and clinical immunology 137.5 (2016): 1347-1358.
⁸Matsusaka, Masako, et al. “Subphenotypes of type 2 severe asthma in adults.” The Journal of Allergy and Clinical Immunology: In Practice 6.1 (2018): 274-276.
⁹Khan, Asif et al. “Type 2 inflammation-related comorbidities among patients with asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis.” European Respiratory Journal 2020; 56: Suppl. 64, 232.
¹⁰Silverberg, Jonathan I. Comorbidities and the impact of atopic dermatitis. Annals of Allergy, Asthma & Immunology. 2019.
¹¹Bieber T. Mechanisms of disease: atopic dermatitis. N Engl J Med. 2008; 358:1483-9.
¹²Gittler, J. K. et al. (2012). Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. The Journal of allergy and clinical immunology, 130(6), 1344-1354.
¹³Bjermer L. Time for a paradigm shift in asthma treatment: from relieving bronchospasm to controlling systemic inflammation. Journal of Allergy and clinical Immunology. 2007 Dec 1;120(6):1269-75.
¹⁴Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, Toppila-Salmi S, Bernal-Sprekelsen M, Mullol J, Alobid I, Anselmo-Lima WT. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58:I-+.
¹⁵Huang E, Ong PY. Severe atopic dermatitis in children. Current allergy and asthma reports. 2018 Jun;18(6):1-8.
¹⁶von Mutius E. The burden of childhood asthma. Archives of disease in childhood. 2000; 82(suppl 2):ii2-ii5.
¹⁷Menard-Katcher P, Marks KL, Liacouras CA, Spergel JM, Yang YX, Falk GW. The natural history of eosinophilic oesophagitis in the transition from childhood to adulthood. Alimentary pharmacology & therapeutics. 2013
¹⁸Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):226-232.
¹⁹Sanz de Burgoa V, Rejas J, Ojeda P. Self-perceived sleep quality and quantity in adult subjects with asthma: Findings from the CosteAsma study. J Investig Allergol Clin Immunol. 2016;25(4).
²⁰Lucendo AJ, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J. 2017;5(3):335-358.
²¹Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2022. Available at:
https://ginasthma.org/gina-reports/ . Accessed: July 2022
²²Sidbury R, Tom WL, Bergman JN, Cooper KD, Silverman RA, Berger TG, Chamlin SL, Cohen DE, Cordoro KM, Davis DM, Feldman SR. Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches. Journal of the American Academy of Dermatology. 2014 Dec 1;71(6):1218-33.
²³European Respiratory Society. European Lung White Book, Chapter 2: The economic burden of lung disease. Available at: https://www.ershwhitebook.org/chapters/the-economic-burden-of-lung-disease/ . Accessed: June 2021.
²⁴Eckert L, Gupta S, Gadkari A, Mahajan P, Gelfand JM. Burden of illness in adults with atopic dermatitis: Analysis of National Health and Welness Survey data from France, Germany, Italy, Spain, and the United Kingdom. J Am Acad Dermatol. 2019;81(1):187-195.
²⁵Mukkada V, et al. Health-Related Quality of Life and Costs Associated With Eosinophilic Esophagitis: A Systematic Review. Clin Gastroenterol Hepatol. 2018;16(4):]495-503.
²⁶Milton B et al. The social and economic consequences of childhood asthma across the lifecourse: a systematic review. Child: care, health and development. 2004 Nov;30(6):711-28.
²⁷Daugherty, Jonas, et al. “The impact of long-term systemic glucocorticoid use in severe asthma: a UK retrospective cohort analysis.” Journal of Asthma 55.6 (2018): 651-658.
²⁸Hirano I, Chan ES, Rank MA, Sharaf RN, Stollman NH, Stukus DR, Wang K, Greenhawt M, Falck-Ytter YT, Chachu KA, Day L. AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. Gastroenterology. 2020 May 1;158(6):1776-86.
²⁹Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, Chamlin SL, Cooper KD, Feldman SR, Hanifin JM, Krol A. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. Journal of the American Academy of Dermatology. 2014 Aug 1;71(2):327-49.
³⁰Menzies-Gow A, Canonica GW, Winders TA, de Sousa JC, Upham JW, Fink-Wagner AH. A charter to improve patient care in severe asthma. Advances in therapy. 2018 Oct;35(10):1485-96.
³¹Staikuniene J, et al. Association of chronic rhinosinusitis with nasal polyps and asthma: clinical and radiological features, allergy and inflammation markers. Medicina (Kaunas) 2008; 44(4):257-265.
³²Liu, Jing Nan, et al. The prevalence of serum specific IgE to superantigens in asthma and allergic rhinitis patients. Allergy, Asthma & Immunology Research. 2014;6(3):263-266.
³³Schleimer, Robert P., and Sergejs Berdnikovs. Etiology of epithelial barrier dysfunction in patients with type 2 inflammatory diseases. Journal of Allergy and Clinical Immunology. 2017;139(6):1752-1761.
³⁴Sugita K, Kabashima K. Tight junctions in the development of asthma, chronic rhinosinusitis, atopic dermatitis, eosinophilic esophagitis, and inflammatory bowel diseases. Journal of leukocyte biology. 2020 May;107(5):749-62.
³⁵Eichenfield, Lawrence F., et al. “Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis.” Journal of the American Academy of Dermatology 70.2 (2014): 338-351
³⁶National Institutes of Health (NIH). Health Topics: Atopic Dermatitis. Available at: https://www.niams.nih.gov/health-topics/atopic-dermatitis. Last accessed June 2021.
³⁷Nordin S, Hedén Blomqvist E, Olsson P, Stjärne P, Ehnhage A, NAF2S2 Study Group. Effects of smell loss on daily life and adopted coping strategies in patients with nasal polyposis with asthma. Acta oto-laryngologica. 2011 Aug 1;131(8):826-32.
³⁸Wang R, Hirano I, Doerfler B, Zalewski A, Gonsalves N, Taft T. Assessing adherence and barriers to long-term elimination diet therapy in adults with eosinophilic esophagitis. Digestive diseases and sciences. 2018 Jul;63(7):1756-62.
³⁹Prussin C, Lee J, Foster B. Eosinophilic gastrointestinal disease and peanut allergy are alternatively associated with IL-5+ and IL-5- TH2 responses. Journal of allergy and clinical immunology. 2009 Dec 1;124(6):1326-32.
⁴⁰Mayo Clinic. Peanut Allergy. Available at: https://www.mayoclinic.org/diseases-conditions/peanut-allergy/symptoms-causes/syc-20376175. Accessed June 2021.
⁴¹Seys, Sven F., et al. “Cluster analysis of sputum cytokine-high profiles reveals diversity in T (h) 2-high asthma patients.” Respiratory research 18.1 (2017): 1-10.
⁴²Jackson DJ, Aljamil N, Roxas C, et al. The ‘T2-low’ asthma phenotype: could it just be T2-high asthma treated with corticosteroids? Thorax. 2018;73(suppl 4):A124-A125
⁴³M. Suárez-Fariñas, N. Dhingra and J. Gittler, “Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis,” Journal of Allergy and Clinical Immunology, vol. 132, no. 2, pp. 361-70, 2013.
⁴⁴M. Chaaban, E. M. Walsh and B. A. Woodworth, “Epidemiology and differential diagnosis of nasal polyps.,” American Journal of Rhinology & Allergy, vol. 27, no. 6, pp. 473-478, 2013.
⁴⁵Chehade M, et al. Phenotypic Characterization of Eosinophilic Esophagitis in a Large Multicenter Patient Population from the Consortium for Food Allergy Research. J Allergy Clin Immunol Pract. 2018;6(5):1534-1544.
⁴⁶Pereira MP, et al. Chronic nodular prurigo: clinical profile and burden. A European cross‐sectional study. [published online ahead of print, 2020 Feb 20]. J Eur Acad Dermatol Venereol. 2020.
⁴⁷Zeidler C, et al. Chronic prurigo of nodular type: a review. Acta Derm Venereol. 2018;98(2):173-179.
⁴⁸Pereira MP, et al. European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology
WEBSITE INTEDED AUDIENCE
This Website is available to adults globally.
This website, including any advice and recommendations on the Website, is intended solely as a general educational aid to raise awareness about certain type 2 inflammatory diseases.
The information on this Website is not intended as medical or healthcare advice, or to be used for medical diagnosis or treatment, for any individual problem. It is also not intended as a substitute for professional advice and services from a qualified healthcare provider familiar with your unique facts. Always seek the advice of your doctor or other qualified healthcare provider regarding any medical condition and before starting any new treatment. Your use of the site is subject to the additional disclaimers and caveats that may appear throughout the Website.
We assume no responsibility for any consequence relating directly or indirectly to any action or inaction you take based on the information, services, or other material on the Website. While we strive to keep the information on the Website accurate, complete, and up-to-date, we do no give any assurances, and will not be responsible for, any damage or loss related to the accuracy, completeness, or timeliness of the information on the Website.
You may not copy, change or ruse the Website, any updates to them or any part of them including the software incorporated in them.
In addition, you agree not to:
1. use this Website in any manner that could disable, overburden, damage, or impair this Website, or interfere with any other use of this Website, including, any user’s ability to engage in real-time activities through this Website;
2. use any robot, spider or other automatic device, process or means to access this Website for any purpose, including to scrape, date mine, monitor or copy any of the material on this Website;
3. use any manual process to monitor or copy any of the material on this Website, or to engage in any other unauthorized purpose without the express prior written consent of Site Owner;
4. otherwise use any device, software or routine that interferes with the proper working of this Website; or
5. other attempt to interfere with the proper working of this Website.
We reserve all rights not expressly granted to you.
PRIVACY AND CONSENT TO USE DATA
To the extent personal data is obtained through the website, Genzyme Corporation is data controller for the processing of that personal data.
50 Binney Street,
Cambridge, Massachusetts 02142
Tel.: +1 (617) 252-7500
Microsoft Nederland B.V. Evert van de Beekstraat 354
1118 CZ Schiphol (Amsterdam) The Netherlands
The information communicated on the Website constitutes an electronic communication. When you communicate with us through the Website or via other forms of electronic media, such as e-mail, you are communicating with us electronically. You agree that we may communicate electronically, subject to local privacy laws, and that such communications, as well as notices, disclosures, agreements, and other communications that we provide to you electronically, are equivalent to communications in writing and shall have the same force and effect as if they were in writing and signed by the party sending the communication.
DISCLAIMER OF WARRANTIES WITH RESPECT TO USE OF WEBSITE
The Website is provided on an “as is” and “as available” basis. Except as specifically provided herein, to the fullest extent permissible pursuant to applicable, Site Owner expressly disclaims all warranties of any kind, whether express, legal or implied, including, without limitation, any warranties of merchantability, fitness for a particular purpose and non-infringement.
Site owner does not make any warranty that the Website will meet your requirements, or that access to the Website will be uninterrupted, timely, secure, or error-free, or that defects, if any, will be corrected. Site owner makes no warranties as to the results that may be obtained from the use of the Website or as to the accuracy, quality, or reliability of any information obtained through the website.
You understand and agree that any material and/or data downloaded or otherwise obtained through the use of the Website is used at your own risk and that you will be solely responsible for any damage to your computer system or loss of data that results from the download of such material and/or data.
No advice or information, whether oral or written, obtained by you from Site Owner or through the Website shall create any warranty not expressly made herein.
LIMITATIONS OF LIABILTY
You expressly understand agree that under no circumstances will Site Owner, its affiliates and any of their respective directors, officers, employees, agents, mandataries or other representatives be liable for direct, indirect, special, incidental, consequential, punitive or aggravated damages, including, without limitiation, any loss of use, loss of income, saving or profits, loss of data, loss of goodwill, cost of procurement of substitute services, or any other indirect, special, incidental, or consequential damages, howsoever caused, and on any theory of liability, whether for breach of contract, tort (including negligence and strict liability), or otherwise resulting from (1) the use of, or the inability to use, the Website; (2) the cost of procurement of substitute services, items, or websites; (3) unauthorized access to or alteration of your transmission or data (including personal information); (4) the statements or conduct of any third party on the Website; or (5) any other matter relating to the Website. These limitations will apply whether or not Site Owner has been advised of the possibility of such damages and notwithstanding any failure of essential purpose of any limited remedy. This exclusion of liability shall apply to the fullest extent permitted by applicable laws.
The trademarks and brand names displayed on this Website are the property of Site Owner, its affiliates or third party owners. You may use or display any trademarks or service marks owned by Site Owner without our prior written consent. You may not use or display any other trademarks or service marks displayed on this Website without the permission of their owners.
MODIFICATION OR SUSPENSION OF THE WEBSITE
We will make reasonable efforts to make the Website available but we may from time to time need to interrupt, restrict, modify or discontinue, temporarily or permanently the Website or parts of it without notice. We will not be responsible for any harm or loss you may suffer as a result of such actions.
LINKS TO THIRD PARTY SITES
MODIFICATIONS TO THESE TERMS
SEVERABILITY OF AGREEMENT
All Sections shall survive the termination of the right to use the Website.
APPLICABLE LAW AND JURISDICTION
As part of its day-to-day operation, SANOFI provides access to a variety of tools and resources which are destined to provide information to all the individuals with whom it has business interactions with (patients and their relatives, participants to clinical trials, healthcare professionals, users of products and services, workers, etc.) regarding its activities.
Such tools and resources may be provided in various formats, including, more specifically in electronic format and by means of online electronic communications, including the website available at www.sanofi.com and any other website made available by SANOFI and to which this policy applies (hereinafter together the “Website”). In order to be able to provide them, SANOFI is fully committed to the protection of Personal Data and intends to provide you with all relevant information regarding the way in which SANOFI processes your Personal Data on the Website.
WHO IS RESPONSIBLE FOR THE PROCESSING OF PERSONAL DATA ON THIS WEBSITE (THE CONTROLLER)?
Genzyme Corporation is responsible for the processing of Personal Data of individuals using this website and therefore acts as the Controller:
50 Binney Street,
Cambridge, Massachusetts 02142
Tel.: + 1 (617) 252-7500
REMINDER: WHAT IS PERSONAL DATA & PROCESSING?
In this respect, the notion of “processing” designates any action that is undertaken on your Personal Data such as, for instance:
WHAT PERSONAL DATA DOES THIS WEBSITE COLLECT?
When operating, this Website may collect the following categories of Personal Data:
In addition, this website embeds poll functionality which asks survey questions regarding health conditions. The responses to the survey questions are collected anonymously and aggregated with other responses in order to show collective results. The poll is multiple-choice with no option for free text.
FOR WHAT PURPOSES DOES THIS WEBSITE COLLECT PERSONAL DATA?
Any processing of Personal Data must be implemented for a defined purpose. In this respect, the collection and processing of Personal Data on this Website is conducted for the following purposes:
ON WHAT GROUNDS DOES THIS WEBSITE PROCESS YOUR PERSONAL DATA?
For the purposes of this Website, your Personal Data is only processed on the basis of:
HOW LONG IS THE PERSONAL DATA COLLECTED ON THIS WEBSITE RETAINED?
The Personal Data collected on this Website will be retained for the following periods, depending on the categories of Personal Data processed
WHO HAS ACCESS TO PERSONAL DATA
SANOFI may transfer your Personal Data both internally (i.e. to other SANOFI entities) and/or externally to third party service providers for the purposes outlined above.
Where such internal or external transfer of Personal Data implies the transfer of your Personal Data to a country providing a lower level of protection to Personal Data than generally afforded in your jurisdiction, SANOFI will ensure that a sufficient level of protection is provided to your Personal Data by implementing adequate safeguards such as the European Standard Contractual Clauses, the SANOFI Binding Corporate Rules or asking for your prior explicit consent.
YOUR RIGHTS: SANOFI WILL ENSURE THAT YOU CAN EXERCISE YOUR RIGHTS PERTAINING TO YOUR PERSONAL DATA
You can exercise your rights as provided by applicable data protection laws.
To that end, SANOFI informs you that you are entitled:
if you would like to exercise any of these rights, please contact us as described in the “How to Contact Us” section below and we will take necessary steps to respond as soon as possible.
You may also file a complaint before a competent data protection authority regarding the processing of your Personal Data. While we suggest that you contact us beforehand, if you wish to exercise this right, you shoud contact directly the competent data protection authority.
HOW TO CONTACT US